SYDNEY, AUSTRALIA - NOVEMBER 17: Wegovy is produced by pharmaceutical company Novo Nordisk and has been approved for ...

Novo Holdings, parent company of the pharmaceutical giant Novo Nordisk, is spending $16.5 billion on the acquisition. It will ...

Danish drugmaker Novo Nordisk (NVO) is investing $1.20 billion U.S. in a new facility that will produce medications to treat ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 496.78% and ...

Part of the joy of the season may be gone — or feel different — for people who are taking popular weight-loss drugs and can't ...

Here are five things to know about GLP-1s and increased healthcare utilization: 1. According to the report, an uptick in GLP-1 use is facilitating a range of "crucial preventive care," including pap ...

New weight-loss medications are reshaping U.S. healthcare by increasing diagnoses of obesity-related conditions and encouraging patients' engagement with health services. These drugs, including Wegovy ...

The Danish Medicines Agency had been watching reports of a rare eye disease in patients who took Novo’s GLP-1 drug but until ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk (NVO) is making headlines with its inventive investment of $1.2 billion aimed at building a new production ...

Investors' focus could, however, shift back onto the possible market impacts of GLP-1 agonists in 2025, particularly as a result of a major expansion of current supplies after Novo Nordisk was given a ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.